HVE.F Innoviva Inc.

Healthcare Biotechnology Frankfurt Exchange
16.90 EUR
Close of Nov 12, 2026
16.20 21.20
Market cap
EUR 1.20B
P/E
8.5x
P/B
1.18x
ROE
3.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is HVE.F undervalued?

Graham number
Price16.90
Graham value25.41
Discount33.5%

HVE.F trades 33.5% below its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Innoviva Inc. fundamental analysis

No fundamental analysis for Innoviva Inc. yet.

Innoviva Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Innoviva Inc.

Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic o…

Full company profile